Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06994676 · ClinicalTrials.gov registry record · Phase 1

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

A Phase 1 study of Chronic Myeloid Leukemia and High Risk Myelodysplastic Syndrome, sponsored by Crossbow Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
72
Enrollment target
11
Study locations

NCT06994676 is a Phase 1 study of Chronic Myeloid Leukemia and High Risk Myelodysplastic Syndrome that is actively recruiting participants, run by Crossbow Therapeutics. The registered enrollment target is 72 participants, below the 208-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (65% lower). The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06994676, a Phase 1 study of Chronic Myeloid Leukemia and High Risk Myelodysplastic Syndrome, is actively recruiting participants, sponsored by Crossbow Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
72 participants
Enrollment target
11
Study locations

Study Summary

Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.

Conditions Studied

Chronic Myeloid Leukemia High Risk Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia (CMML) AML (Acute Myeloid Leukemia)

Interventions

  • DRUG CBX-250

Study Locations (11)

California

  • City of Hope - Duarte
  • Stanford Medical Center - Palo Alto

Tennessee

  • Sarah Cannon Cancer Institute - Nashville
  • Vanderbilt University Medical Center - Nashville

Florida

  • Moffitt Cancer Center - Tampa

Illinois

  • Northwestern Medicine - Chicago

Massachusetts

  • Dana Farber Cancer Institute - Boston

Missouri

  • Washington University in St. Louis - St Louis

New York

  • Memorial Sloan Kettering Cancer Center - New York

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2025-07-16
Est. Completion 2027-06
Phase Phase 1

Sponsor

Crossbow Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06994676

The ClinicalTrials.gov registry entry for NCT06994676 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 208-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (65% lower). The listed sponsor is Crossbow Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which CBX-250 is the first listed.

NCT06994676 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Tennessee, Florida.

Frequently Asked Questions

What is clinical trial NCT06994676 about?

NCT06994676 is a clinical study titled "A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias". Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be admini...

What is the current status of trial NCT06994676?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-07-16. Estimated completion is 2027-06.

What conditions does trial NCT06994676 study?

This clinical trial studies the following conditions: Chronic Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML (Acute Myeloid Leukemia).

What interventions are being tested in trial NCT06994676?

The interventions under investigation include: CBX-250 (DRUG).

Who is sponsoring clinical trial NCT06994676?

This trial is sponsored by Crossbow Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06994676 being conducted?

This trial has 11 study locations across California, Florida, Illinois, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Myeloid Leukemia

All registered trials for this condition

High Risk Myelodysplastic Syndrome

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.